Literature DB >> 26707564

[Subjective cognitive impairment and Alzheimer's disease: a two year follow up of 51 subjects during two years].

Nathalie Sambuchi1, Isabelle Muraccioli2, Béatrice Alescio-Lautier3, Véronique Paban4, Roland Sambuc5, Élisabeth Jouve5, Yonas Endale Geda6, Ronald Karl Petersen7, Bernard François Michel8.   

Abstract

Subjective cognitive impairment (SCI) is defined by a state of subjective complaint, without objective cognitive deterioration. Amnestic mild cognitive impairment (A-MCI), which characterizes a syndrome between normal cognitive aging and early Alzheimer's disease (E-AD), is preceded by A-MCI from many years. SCI expresses a metacognitive impairment. A cohort of 51 subjects [7 normal controls (NC), 28 SCI, 12 A-MCI and 5 E-AD] was followed up during 24 months, with a neuropsychological evaluation each 6 months during 1 year (V1, V2, V3), then 1 year later (V4). Among the 28 SCI, 6 converted to A-MCI at V4 (21.42%), 1 to A-MCI-A at V3, then to E-AD at V4. These results suggest a continuum from SCI to A-MCI, and E-AD. Progressive SCI differed from non-progressive SCI on verbal episodic memory and executive functions tests at the initial examination. MRI showed anterior cingular atrophy in all SCI patients but hippocampal atrophy was only observed in 20 patients. Our results suggest that metacognition impairment is the expression of a dysfunction in the anterior pre-frontal cortex, in correlation with a syndrome of hyper-attention.

Entities:  

Keywords:  Alzheimer's disease; amnestic mild cognitive impairment; anterior cingular cortex; memory complaint; metacognition; subjective cognitive impairment

Mesh:

Year:  2015        PMID: 26707564     DOI: 10.1684/pnv.2015.0575

Source DB:  PubMed          Journal:  Geriatr Psychol Neuropsychiatr Vieil        ISSN: 2115-7863


  1 in total

1.  Diagnosis of Alzheimer's disease with Electroencephalography in a differential framework.

Authors:  Nesma Houmani; François Vialatte; Esteve Gallego-Jutglà; Gérard Dreyfus; Vi-Huong Nguyen-Michel; Jean Mariani; Kiyoka Kinugawa
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.